Boston, MA 08/26/2014 (wallstreetpr) – Kite Pharma Inc (NASDAQ:KITE) welcomes the good news of positive results coming from its clinical trial of cancer treatment. The shares surged more than 20% on the news in after-hours trading. Also, Kite Pharma has plans to file a new drug application for the clinical trial of KTE-C19 drug. It is a treatment drug for the patients suffering from large B-cell lymphoma who have not responded to the two or more lines of therapy.
The study
Kite Pharma Inc (NASDAQ:KITE) treated fifteen patients suffering from aggressive non-Hodgkin’s lymphoma with its cancer drug in Phase 1-2a clinical trial. In the study, eight patients were in complete remission while the four patients were in partial remission. The results of the study were published in the Journal of Clinical Oncology.
The clinical trial was conducted by the National Cancer Institute and was self-funded by Kite. Out of the fifteen patients, thirteen patient’s results were evaluable. The group consists of two patients who were re-treated in the trial. Kite Pharma Inc (NASDAQ:KITE) was formed in 2009, and it primarily develops the treatment therapy that uses the patient’s immune system for treating cancer.
The management view
David Chang, Executive Vice President, Research & Development, and CMO of Kite Pharma Inc (NASDAQ:KITE), said that Kite and the NCI together have conducted studies to find the effective treatments for solid tumors and blood cancers. The results of the studies and the response rate are encouraging. Also, the remission durability of the disease was noteworthy.
Chang further said that there is much potential in its anti-CD19-CAR T cell approach for treating B cell malignancies. The results are especially significant as they successfully treated the patients suffering from relapsed, refractory lymphomas. The success of the Phase 1-2a clinical trial has encouraged Kite to file an IND in the last quarter of the year. It will be Phase 1-2 clinical trial of KTE-C19 in patients with DLBCL. The patient enrollment for a clinical trial will start in the first half of 2015.
